Poziotinib Maintains High Response Rate Against Harmful Lung Cancer Mutation
University of Texas MD Anderson Cancer CenterA drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide unprecedented response rates among stage 4 non-small cell lung cancer patients with genetic mutations that have previously defied treatment.